We are live on
!
Find out more
EFIC
Eliot Finkel Investment Counsel Portfolio holdings
AUM
$214M
1-Year Est. Return
62.72%
This Fund
S&P 500
This Quarter
Est. Return
+10.51%
1 Year Est. Return
+62.72%
3 Year Est. Return
+88.94%
5 Year Est. Return
+113.54%
10 Year Est. Return
+327.62%
AUM
$149M
AUM Growth
+$15.2K
(+0.01%)
Cap. Flow
-$13.6M
Cap. Flow
% of AUM
-9.12%
Top 10 Holdings %
Top 10 Hldgs %
55.37%
Holding
32
New
–
Increased
–
Reduced
28
Closed
2
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$5.28M |
| 2 |
Pfizer
PFE
|
+$4.95M |
| 3 |
Corning
GLW
|
+$447K |
| 4 |
US Bancorp
USB
|
+$246K |
| 5 |
PACCAR
PCAR
|
+$219K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 49.56% |
| 2 | Healthcare | 12.59% |
| 3 | Technology | 11.53% |
| 4 | Materials | 6.42% |
| 5 | Utilities | 5.13% |
Similar funds
IH
CMBA
TSS
SIA
RC
IAM
VFG
PFA
Eliot Finkel Investment Counsel's Q4 2023 Portfolio in Review
As of Q4 2023, Eliot Finkel Investment Counsel held 32 positions worth $149M, up 0.01% from $149M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Eliot Finkel Investment Counsel withdrew a net $13.6M in Q4 2023, closing 2 positions and reducing 28 holdings. Its most notable exit was CVS Health, an estimated $5.28M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 50% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.
- Eliot Finkel Investment Counsel's biggest Q4 2023 reduction was Corning, cutting an estimated $447K.
- Eliot Finkel Investment Counsel fully exited CVS Health in Q4 2023, selling an estimated $5.28M.
- Eliot Finkel Investment Counsel's ten largest holdings make up 55% of its $149M portfolio in Q4 2023.
- Eliot Finkel Investment Counsel opened 0 new positions and closed 2 in Q4 2023.
- Eliot Finkel Investment Counsel's portfolio value rose 0.01% quarter-over-quarter to $149M.
Based on Eliot Finkel Investment Counsel's 13F filing for Q4 2023, filed 18 Jan 2024.